Nanoform Finland Oyj (NANOFH.HE)
EUR 1.29
(2.7%)
EUR 1.29
(2.7%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -7.97 Million EUR | 87.1% |
| 2022 | -61.8 Million EUR | 9.2% |
| 2021 | -68.06 Million EUR | -25.69% |
| 2020 | -54.15 Million EUR | -1387.83% |
| 2019 | -3.63 Million EUR | -13.95% |
| 2018 | -3.19 Million EUR | -587.27% |
| 2017 | 655.58 Thousand EUR | 1959.4% |
| 2016 | -35.25 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -24.48 Million EUR | -233.48% |
| 2024 Q1 | -7.34 Million EUR | 7.94% |
| 2023 Q2 | -37.39 Million EUR | 32.32% |
| 2023 FY | -7.97 Million EUR | 87.1% |
| 2023 Q4 | -7.97 Million EUR | 34.1% |
| 2023 Q3 | -12.1 Million EUR | 67.64% |
| 2023 Q1 | -55.24 Million EUR | 10.61% |
| 2022 Q1 | -84.21 Million EUR | -23.71% |
| 2022 Q4 | -61.8 Million EUR | 10.71% |
| 2022 Q3 | -69.21 Million EUR | 8.59% |
| 2022 Q2 | -75.72 Million EUR | 10.07% |
| 2022 FY | -61.8 Million EUR | 9.2% |
| 2021 FY | -68.06 Million EUR | -25.69% |
| 2021 Q4 | -68.06 Million EUR | 8.98% |
| 2021 Q3 | -74.78 Million EUR | 9.42% |
| 2021 Q2 | -82.56 Million EUR | 6.32% |
| 2021 Q1 | -88.13 Million EUR | -62.74% |
| 2020 FY | -54.15 Million EUR | -1387.83% |
| 2020 Q2 | -69.75 Million EUR | -11705.66% |
| 2020 Q4 | -54.15 Million EUR | 9.4% |
| 2020 Q3 | -59.77 Million EUR | 14.3% |
| 2020 Q1 | 601 Thousand EUR | 116.51% |
| 2019 Q4 | -3.63 Million EUR | 0.0% |
| 2019 Q1 | 5.59 Million EUR | 0.0% |
| 2019 FY | -3.63 Million EUR | -13.95% |
| 2018 FY | -3.19 Million EUR | -587.27% |
| 2017 FY | 655.58 Thousand EUR | 1959.4% |
| 2016 FY | -35.25 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Biohit Oyj | -2.3 Million EUR | -246.704% |
| Herantis Pharma Oyj | -5.46 Million EUR | -45.828% |